{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-000002","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.345651+00:00","generated_at":"2026-06-07T05:41:50.064941+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer","bullets":["Received $13.0 million in milestone payments from Heska Corporation.","Milestone triggered by successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ point-of-care platform.","Payment stems from March 2022 License and Supply Agreement between Belgian Volition SRL and Heska.","Test is marketed as the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-000002","json":"https://secwatch.observer/filing/0001477932-24-000002.json","markdown":"https://secwatch.observer/filing/0001477932-24-000002.md","text":"https://secwatch.observer/filing/0001477932-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/0001477932-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:41:50.064941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}